Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow

International Journal of Drug Policy

Volumn 23, Issue 5, 2012, Pages 353-357

  McDonald, Scott A ^a,b   Hutchinson, Sharon J ^a,b   Cameron, Sheila O ^c   Innes, Hamish A ^a,b   McLeod, Allan ^a   Goldberg, David J ^a  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Epidemiology; Hepatitis C virus; Incidence; Intravenous substance abuse

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FEMALE; GLASGOW OUTCOME SCALE; HEPATITIS C; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; REINFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VIRAL CLEARANCE;

ADULT; ANTIVIRAL AGENTS; DATABASES, FACTUAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; MALE; POISSON DISTRIBUTION; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; RNA, VIRAL; SCOTLAND; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84866175363     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2012.02.003     Document Type: Article

References (34)

1. Aitken C.K., Tracy S.L., Revill P., Bharadwaj M., Bowden D.S., Winter R.J., et al. Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user. Journal of Clinical Virology 2008, 41(4):293-296.
2. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine 1999, 341(8):556-562.
3. Backmund M., Meyer K., Edlin B.R. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clinical Infectious Diseases 2004, 39(10):1540-1543.
4. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436(7053):946-952.
5. Corson S., Greenhalgh D., Palmateer N., Weir A., Hutchinson S. Risk of hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: A systematic review. The International Journal on Drug Policy 2011, 22(2):102-108.
6. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118(2):346-355.
7. Currie S.L., Ryan J.C., Tracy D., Wright T.L., George S., McQuaid R., et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug and Alcohol Dependence 2008, 93(1-2):148-154.
8. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clinical Infectious Diseases 2005, 40(Suppl. 5):S336-S338.
9. Dore G.J., MacDonald M., Law M.G., Kaldor J.M. Epidemiology of hepatitis C virus infection in Australia. Australian Family Physician 2003, 32(10):796-798.
10. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258(5079):135-140.
11. Goldberg D., Davis B., Allardice G., McMenamin J., Codere G. Monitoring the spread of HIV and AIDS in Scotland 1983-1994. Scottish Medical Journal 1996, 41(5):131-138.
12. Golub E.T., Strathdee S.A., Bailey S.L., Hagan H., Latka M.H., Hudson S.M., et al. Distributive syringe sharing among young adult injection drug users in five U.S. cities. Drug and Alcohol Dependence 2007, 91(Suppl. 1):S30-S38.
13. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006, 44(5):1139-1145.
14. Grebely J., Knight E., Ngai T., Genoway K.A., Raffa J.D., Storms M., et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. Journal of Gastroenterology and Hepatology 2010, 25(7):1281-1284.
15. Hay G., Gannon M., Casey J., McKeganey N. Estimating the national and local prevalence of problem drug misuse in Scotland: Executive report 2009, University of Glasgow, Glasgow.
16. Health Protection Agency (2009). Hepatitis C in UK: Annual report 2009.
17. Health Protection Agency Hepatitis C in UK 2011 2011, Health Protection Agency, London.
18. Hutchinson S., McIntyre P., Molyneaux P. Prevalence of hepatitis C among injectors in Scotland 1989-2000: Declining trends among young injectors halt in the late 1990s. Epidemiology and Infection 2002, 128(3):473-477.
19. Lum P.J., Sears C., Guydish J. Injection risk behavior among women syringe exchangers in San Francisco. Substance Use & Misuse 2005, 40(11):1681-1696.
20. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 2002, 359(9316):1478-1483.
21. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. Journal of Viral Hepatitis 2006, 13(1):34-41.
22. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. Journal of Viral Hepatitis 2007, 14(6):413-418.
23. Osburn W.O., Fisher B.E., Dowd K.A., Urban G., Liu L., Ray S.C., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138(1):315-324.
24. Page K., Hahn J.A., Evans J., Shiboski S., Lum P., Delwart E., et al. Acute hepatitis C virus infection in young adult injection drug users: A prospective study of incident infection, resolution, and reinfection. Journal of Infectious Diseases 2009, 200(8):1216-1226.
25. R Development Core Team R: A language and environment for statistical computing 2008, R Foundation for Statistical Computing, Vienna; Austria.
26. Rahman F., Heller T., Sobao Y., Mizukoshi E., Nascimbeni M., Alter H., et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004, 40(1):87-97.
27. Roy K.M., Goldberg D., Taylor A., Hutchinson S., MacDonald L., Wilson K.S., et al. A method to detect the incidence of hepatitis C infection among injecting drug users in Glasgow 1993-98. Journal of Infection 2001, 43(3):200-205.
28. Scottish Government The sexual health and blood borne virus framework, 2011-15 2011, Scottish Government, Edinburgh.
29. Scottish Government Health Department Hepatitis C action plan for Scotland: Phase II: May 2008-March 2011 2008, Scottish Government, Edinburgh.
30. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461(7265):798-801.
31. Trepo C., Pradat P. Hepatitis C virus infection in Western Europe. Journal of Hepatology 1999, 31(Suppl. 1):80-83.
32. University of the West of Scotland Health Protection Scotland West of Scotland Specialist Virology Centre The needle exchange surveillance initiative (NESI): Prevalence of HCV, HIV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2008/2009 2010, University of the West of Scotland, Glasgow.
33. van de Laar T.J., Molenkamp R., van den Berg C., Schinkel J., Beld M.G., Prins M., et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. Journal of Hepatology 2009, 51(4):667-674.
34. Zeremski M., Shu M.A., Brown Q., Wu Y., Des Jarlais D.C., Busch M.P., et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. Journal of Viral Hepatitis 2009, 16(1):10-20.